|
|
Article: Cephalon Receives FDA Approval to Market Sugar-Free Formulation of ACTIQ(R).
- Article from:
- PR Newswire
- Article date:
- September 12, 2005
CopyrightCOPYRIGHT 2005 PR Newswire Association LLC. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan. All inquiries regarding rights should be directed to the Gale Group. (Hide copyright information)
|
FRAZER, Pa., Sept. 12 /PRNewswire-FirstCall/ -- Cephalon, Inc. announced today that it has received an approval letter from the U.S. Food and Drug Administration (FDA) to market a new sugar-free formulation of ACTIQ(R) (oral transmucosal fentanyl citrate) [C-II]. The sugar-free formulation, which is bioequivalent to the currently available product, will be marketed for the same indication as ACTIQ using the same name.
"With this approval, we will move forward with our plans to launch the sugar-free formulation of ACTIQ in the first half of 2006," said Dr. Paul Blake, Executive Vice President, Worldwide Medical & Regulatory Operations. "We are pleased that we are ...